California Patent of the Month – April 2024
MedAbome, Inc, a pioneering entity in biotechnology, has been granted a patent for their therapeutic cancer treatment agent. The invention, a binding agent targeting Transferrin Receptor 1 (TfR1), holds immense promise in the realm of oncology therapeutics.
This innovative binding agent, characterized by a precise molecular architecture, exhibits remarkable specificity and affinity for TfR1, a transmembrane glycoprotein pivotal in regulating iron uptake and cell growth. The agent’s design, encompassing distinctive light and heavy chain variable regions, represents a significant leap forward in antibody engineering.
MedAbome’s invention spans a spectrum of binding agent formats, ranging from monoclonal antibodies to antibody fragments like Fab, Fab’, and F(ab’)2, each tailored to address diverse therapeutic needs. Furthermore, the binding agent’s adaptability extends to conjugation with anti-tumor agents, enhancing its efficacy in combating cancer cells.
The pivotal role of TfR1 in cancer biology underscores the potential impact of this invention. TfR1’s overexpression in various cancer types presents a ripe opportunity for targeted intervention, leveraging MedAbome’s binding agent to disrupt vital cellular processes essential for tumor proliferation.
Preclinical studies have demonstrated the efficacy of MedAbome’s binding agent in inhibiting cancer cell growth, laying the foundation for its translation into clinical applications. Moreover, the development of antibody-drug conjugates, such as MAb11-22.1-S239C-DM1, showcases the versatility of this technology in delivering potent anti-cancer payloads directly to tumor sites.
The journey from laboratory innovation to clinical utility epitomizes MedAbome’s commitment to advancing cancer therapeutics. With its cutting-edge research and development efforts, MedAbome heralds a new era in precision medicine, offering hope to patients and clinicians alike in the fight against cancer.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
